JP2024520727A5 - - Google Patents
Info
- Publication number
- JP2024520727A5 JP2024520727A5 JP2023574780A JP2023574780A JP2024520727A5 JP 2024520727 A5 JP2024520727 A5 JP 2024520727A5 JP 2023574780 A JP2023574780 A JP 2023574780A JP 2023574780 A JP2023574780 A JP 2023574780A JP 2024520727 A5 JP2024520727 A5 JP 2024520727A5
- Authority
- JP
- Japan
- Prior art keywords
- bcma
- domain
- trispecific protein
- approximately
- specifically binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196595P | 2021-06-03 | 2021-06-03 | |
| US63/196,595 | 2021-06-03 | ||
| US202163288124P | 2021-12-10 | 2021-12-10 | |
| US63/288,124 | 2021-12-10 | ||
| PCT/US2022/031917 WO2022256499A2 (en) | 2021-06-03 | 2022-06-02 | Bcma targeting trispecific proteins and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520727A JP2024520727A (ja) | 2024-05-24 |
| JP2024520727A5 true JP2024520727A5 (https=) | 2025-06-10 |
Family
ID=84323567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574780A Withdrawn JP2024520727A (ja) | 2021-06-03 | 2022-06-02 | Ｂｃｍａ標的化三重特異性タンパク質およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240254250A1 (https=) |
| EP (1) | EP4347636A4 (https=) |
| JP (1) | JP2024520727A (https=) |
| AU (1) | AU2022286960A1 (https=) |
| CA (1) | CA3220878A1 (https=) |
| WO (1) | WO2022256499A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| EP3493844A4 (en) | 2016-05-20 | 2021-03-24 | Harpoon Therapeutics Inc. | SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN |
| MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020003915A (es) * | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
| IL315737A (en) * | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CA3089230A1 (en) * | 2018-03-02 | 2019-09-06 | Cdr-Life Ag | Trispecific antigen binding proteins |
-
2022
- 2022-06-02 AU AU2022286960A patent/AU2022286960A1/en active Pending
- 2022-06-02 WO PCT/US2022/031917 patent/WO2022256499A2/en not_active Ceased
- 2022-06-02 EP EP22816832.4A patent/EP4347636A4/en not_active Withdrawn
- 2022-06-02 CA CA3220878A patent/CA3220878A1/en active Pending
- 2022-06-02 JP JP2023574780A patent/JP2024520727A/ja not_active Withdrawn
-
2023
- 2023-11-30 US US18/524,822 patent/US20240254250A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024520727A5 (https=) | ||
| JP2024523003A5 (https=) | ||
| Wilson et al. | Enhancement of tumor radiation response by the antivascular agent 5, 6-dimethylxanthenone-4-acetic acid | |
| JP2024532374A5 (https=) | ||
| AR040603A1 (es) | El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos | |
| JP2008503476A5 (https=) | ||
| US20050244407A1 (en) | Therapeutic synergy of anti-cancer compounds | |
| NZ592039A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| JP2004512262A5 (https=) | ||
| JP2014114288A5 (https=) | ||
| JP2013520442A5 (https=) | ||
| JP2006513184A5 (https=) | ||
| JP2021518394A5 (https=) | ||
| JP2020523354A5 (https=) | ||
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| JP2022523045A5 (https=) | ||
| JP2022523530A5 (https=) | ||
| JP2004537500A5 (https=) | ||
| WO2025061123A1 (zh) | 治疗非霍奇金淋巴瘤的药物组合及其用途 | |
| JP2024016209A5 (https=) | ||
| JP2024517085A5 (https=) | ||
| JP7518816B2 (ja) | 治療抵抗性がんの予防又は治療用の医薬組成物 | |
| JP2023524359A5 (https=) | ||
| JP2021522246A5 (https=) | ||
| JP2003528919A5 (https=) |